| 14.64 -0.17 (-1.15%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.61 | 1-year : | 20.57 |
| Resists | First : | 15.08 | Second : | 17.61 |
| Pivot price | 14.43  |
|||
| Supports | First : | 12.53 | Second : | 10.96 |
| MAs | MA(5) : | 14.76 |
MA(20) : | 14.04 |
| MA(100) : | 10.93 |
MA(250) : | 7.61 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 89.1 |
| RSI | RSI(14): 60.8 |
|||
| 52-week | High : | 15.08 | Low : | 3.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DRTS ] has closed below upper band by 35.8%. Bollinger Bands are 47% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.89 - 14.99 | 14.99 - 15.07 |
| Low: | 14.27 - 14.37 | 14.37 - 14.45 |
| Close: | 14.5 - 14.66 | 14.66 - 14.79 |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Sat, 22 Aug 2026
Price to sales forward of Alpha Tau Medical Ltd. – NASDAQ:DRTS - TradingView
Fri, 21 Aug 2026
Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan - Stock Titan
Tue, 11 Aug 2026
Price to earnings forward of Alpha Tau Medical Ltd – TASE:DRTS - TradingView
Mon, 10 Aug 2026
Alpha Tau Medical (DRTS) widens loss as Tolmar deal boosts cash and milestones - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 30.5 (%) |
| Held by Institutions | 8.9 (%) |
| Shares Short | 3,210 (K) |
| Shares Short P.Month | 2,210 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -141.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -14.08 |
| PEG Ratio | 0 |
| Price to Book value | 30.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -105.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|